Form 4: Madrigal Pharmaceuticals Executive Rebecca Taub Executes Stock Option and Sells Shares Under 10b5-1 Plan

Rebecca Taub, a Director, President of R&D, and CMO at Madrigal Pharmaceuticals, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Rebecca Taub, a Director, President of R&D, and CMO of Madrigal Pharmaceuticals, executed a transaction involving the company's stock on April 8, 2024.
• Taub exercised stock options to acquire 2,676 shares of common stock at a price of $9.45 per share.
• Concurrently, Taub sold a total of 2,676 shares of common stock in multiple transactions at weighted average prices ranging from $243.245 to $248.58 per share.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2023.
• Following these transactions, Taub directly owns 458,999 shares of common stock and indirectly owns 655,540 shares through SQN LLC.
• The shares underlying the stock option are fully vested and exercisable.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. The exercise of options is a positive sign, but the subsequent sale is a neutral event within the context of the 10b5-1 plan.

Positives

• The exercise of stock options demonstrates the executive's confidence in the company.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating transparency and avoiding concerns about insider trading.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.

Industry Context

Executive stock transactions are common in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. Rule 10b5-1 plans are a standard tool to allow insiders to sell shares without raising concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The use of a 10b5-1 trading plan is a common practice among executives to manage their stock sales in a transparent and compliant manner.
• Comparing the volume and timing of these transactions with those of executives at similar pharmaceutical companies (e.g., Viking Therapeutics, Intercept Pharmaceuticals) could provide additional context.

Related Party Transactions

• The Reporting Person and her spouse are each managing members of SQN, LLC, which indirectly holds 655,540 shares.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The use of a 10b5-1 plan ensures transparency and reduces concerns about insider trading, which benefits all stakeholders.

Key Dates